TL;DR
GLP 3 is not the formal name of a hormone, medicine, or FDA-approved drug class. The term usually refers to retatrutide, an investigational medicine that targets GLP-1, GIP, and glucagon receptors. As of October 3, 2026, retatrutide is not FDA approved and has no approved consumer dose or verified retail price. We recommend avoiding products sold as “GLP-3” or retatrutide outside a legitimate clinical trial.
What is GLP 3? The name is not a drug class

“GLP-3” is not the formal name of an approved drug class or a recognized hormone that follows GLP-2.
Searchers and sellers often use GLP 3, triple G, GLP-3R, and GLP-3 RT when referring to retatrutide. The accurate description is an investigational triple receptor agonist. It acts at GLP-1, GIP, and glucagon receptors.
A vial labeled “GLP-3” does not prove that it contains retatrutide. Nor does the label establish its strength, sterility, storage history, approval status, or legal source.
Our rule is straightforward: treat GLP-3 as an informal marketing or search term unless a licensed clinician and pharmacy can identify the exact product.
What “GLP-3,” “triple G,” and “GLP-3 RT” usually mean
These terms commonly point to the same concept:
- GLP-3: Informal shorthand for a medicine with three receptor targets.
- Triple G: A nickname referring to GLP-1, GIP, and glucagon activity.
- GLP-3R: Online shorthand, not an established receptor or drug class.
- GLP-3 RT: Seller terminology that may refer to retatrutide.
- RT: Not an FDA approval mark, generic name, or quality standard.
A listing such as “GLP-3 20 mg RT” may look like a finished prescription product. The wording alone proves nothing about what is in the vial.
Why GLP-2 is not the link between GLP-1 and retatrutide
GLP-1 and GLP-2 are separate hormones. GLP-1 affects glucose control, appetite, and digestion, while GLP-2 primarily supports intestinal function.
Drug development does not follow a GLP-1, GLP-2, GLP-3 sequence. Giving one medicine three receptor targets does not create a hormone called GLP-3.
How retatrutide targets GLP-1, GIP, and glucagon receptors
Retatrutide activates three receptor systems. GLP-1 and GIP are involved in glucose regulation, insulin response, appetite, and food intake. Researchers are also studying how glucagon receptor activity may influence energy use and liver metabolism.
This biology makes retatrutide a promising research subject. It does not prove that every patient would lose more weight or have a better clinical outcome.
One target, two targets, and three targets
The basic distinction is the number and type of receptor targets:
- Semaglutide: GLP-1 receptor agonist.
- Tirzepatide: GIP and GLP-1 receptor agonist.
- Retatrutide: GLP-1, GIP, and glucagon receptor agonist.
Receptor count does not rank overall safety, effectiveness, cost, or suitability. Our retatrutide versus tirzepatide evidence review explains why results from separate trials cannot establish a firm winner.
Why three targets do not guarantee better care
More targets can produce additional effects, but they can also add uncertainty. A useful comparison must consider:
- Side effects and treatment discontinuation
- Contraindications and drug interactions
- Dose escalation and adherence
- Changes in fat and lean mass
- Outcomes after treatment ends
- Long-term cardiovascular evidence
- Uncommon harms that early trials may miss
Mechanism cannot replace direct comparative evidence or an individual clinical assessment.
Is retatrutide FDA approved?

As of October 3, 2026, retatrutide is not FDA approved. Our review found no approved retatrutide product in the FDA database.
Retatrutide has been studied for obesity, type 2 diabetes, and related conditions. However, clinical development, an FDA application, regulatory review, approval, and commercial launch are separate events. A trial result or seller announcement is not an approval decision.
How to verify approval in two minutes
Search the FDA Drugs@FDA database using the generic name and any claimed brand name. An approved record identifies information such as the applicant, dosage form, labeling, and approval history.
Check the indication too. Approval for one condition does not automatically authorize marketing for another.
Clinical-trial access is not retail access
Clinical-trial participants join under eligibility rules, informed-consent requirements, and a controlled research protocol. That is different from routine prescribing and pharmacy dispensing.
A paid peptide listing is not trial enrollment. We recommend verifying studies through ClinicalTrials.gov rather than trusting sellers that use research findings to promote unapproved vials.
What retatrutide trials have found
Controlled studies have reported substantial average weight loss among some participants receiving retatrutide. Research in people with type 2 diabetes has also examined changes in blood glucose and body weight, while related work has evaluated liver fat.
More recent manufacturer-released data have continued to draw attention to retatrutide’s potential. These findings remain research results, not approval decisions or instructions for self-dosing.
Group averages cannot predict one person’s outcome. Results depend on the study population, assigned dose, treatment duration, dose escalation, discontinuations, and statistical method.
How to read weight-loss figures
A headline percentage is not a personal forecast. Trial participants receive defined doses, planned titration, eligibility screening, product controls, and clinical monitoring.
When we review a result, we also look at how many participants stopped treatment, how missing data were handled, and whether the finding came from a peer-reviewed publication or a manufacturer announcement.
What the trials cannot yet answer
Research and regulatory review still need to clarify questions such as:
- Long-term cardiovascular outcomes
- Weight maintenance after stopping treatment
- Uncommon or delayed adverse effects
- Results in broader real-world populations
- Long-term changes in body composition
- Adherence outside controlled trials
We recommend judging retatrutide by the complete evidence and any future FDA-reviewed label, not by its most striking headline.
Retatrutide side effects and unverified-vial risks
Retatrutide studies have reported gastrointestinal problems such as nausea, diarrhea, vomiting, and constipation. Side effects may vary with dose and dose escalation. Researchers have also monitored changes in heart rate.
There are two distinct risks: those associated with the molecule and those created by an unverified product.
An unauthorized vial may contain the wrong amount, another ingredient, contamination, or no retatrutide. Poor handling can also affect sterility and stability. Our guide to weight-loss peptides explains why a plausible chemical name does not establish a safe patient product.
“Research use only” and “not for human consumption” disclaimers do not make self-injection safe.
Why a 20 mg vial label is not a clinical dose
A “20 mg” label may describe the total amount a seller claims is in a vial. It is not necessarily a prescribed injection dose.
Trial protocols use assigned doses, controlled products, step-up schedules, and medical monitoring. Those protocols do not validate a vial marked “RT 20 mg” or provide a safe self-injection plan.
Red flags before purchase or injection
We recommend stopping if a seller has any of these warning signs:
- No prescription requirement
- No named dispensing pharmacy
- No verifiable pharmacy license
- Crypto-only payment
- Dosing advice supplied by the seller
- Missing lot, manufacturer, or storage information
- Human-use claims paired with a research disclaimer
- No adverse-event reporting process
Do not inject a product if its source, identity, storage, or sterility cannot be confirmed. Anyone considering compounded treatment should first review these compounding pharmacy accreditation checks.
Retatrutide vs tirzepatide, semaglutide, cagrilintide, and CagriSema
These treatments differ in mechanism, evidence, and regulatory status.
| Drug or combination | Main target or type | Current general status |
|---|---|---|
| Retatrutide | GLP-1, GIP, and glucagon agonist | Investigational |
| Tirzepatide | GIP and GLP-1 agonist | Approved products available for labeled uses |
| Semaglutide | GLP-1 agonist | Approved products available for labeled uses |
| Cagrilintide | Long-acting amylin analogue | Investigational |
| CagriSema | Cagrilintide plus semaglutide | Investigational |
Separate trials should not be treated as a head-to-head competition.
Retatrutide vs tirzepatide
Retatrutide targets three receptors, while tirzepatide targets two. The clearest practical difference is current access: retatrutide remains investigational, while FDA-approved tirzepatide products are available by prescription for specific uses.
Only direct comparative evidence could support a firm efficacy claim.
Retatrutide vs semaglutide
Retatrutide is a triple receptor agonist. Semaglutide is a GLP-1 receptor agonist with approved products, established prescribing information, and regulated supply chains.
Semaglutide products also have different labels. They should not be treated as automatically interchangeable.
Cagrilintide and CagriSema are different approaches
Cagrilintide is an investigational amylin analogue rather than a GLP-1 or triple receptor agonist. CagriSema combines cagrilintide with semaglutide.
Each product must undergo its own regulatory review. Our cagrilintide approval and evidence guide tracks these distinctions.
GLP-3 cost, dosage, and refill claims
Retatrutide has no verified retail price or approved consumer dose as of October 3, 2026. Those details require an approved product, prescribing label, and commercial launch.
If a seller quotes a price for “GLP-3,” that is the price of its own item—not an established market price for FDA-approved retatrutide. Trial regimens should never be converted into personal dosing instructions.
Questions to ask about a quoted cash price
For an approved treatment, confirm whether the quote includes:
- Clinician review
- Medication and supplies
- Shipping
- Required laboratory work
- Follow-up appointments
- Refills and dose changes
We also recommend confirming the dispensing pharmacy, refill timing, stock policy, and cancellation terms.
Why no seller can set a standard GLP-3 dose
Investigational dosing is controlled through research protocols and oversight. A seller cannot turn those schedules into standard patient care.
An approved dosing schedule comes from reviewed prescribing information. Retatrutide does not yet have an FDA-approved consumer label.
Approved weight-loss options available now
Patients do not have to treat retatrutide as the only option. Depending on eligibility, clinicians may consider approved medicines such as Wegovy, Zepbound, Saxenda, Contrave, Qsymia, or orlistat. Some treatments are intended only for specific medical or genetic conditions.
The right choice depends on health history, current medicines, contraindications, treatment goals, cost, and availability. Product labels also matter: not every medicine containing semaglutide or tirzepatide is approved for weight management.
Patients considering compounded products should review the current compound tirzepatide access and refill rules. Compounded medicines are not the same as FDA-approved generic products and need separate legal and clinical review.
A cash-pay checklist before starting
Confirm these details in writing:
- Prescriber and dispensing pharmacy
- Full recurring charge
- Included medication and supplies
- Shipping schedule
- Price changes at different doses
- Refill lead time
- Plan for delayed or unavailable stock
What to ask before changing medication
Ask why the change is recommended and how progress will be measured. Review side effects, contraindications, current medicines, previous treatment response, and the transition plan.
A backup plan can reduce missed treatment and prevent rushed purchases from unverified sellers.
GLP-3 and retatrutide questions
What is the difference between GLP-1 and GLP-2?
They are separate hormones with different functions. GLP-1 affects glucose regulation, appetite, and digestion. GLP-2 primarily supports intestinal function. GLP-2 is not an intermediate generation between GLP-1 medicines and retatrutide.
Is retatrutide FDA approved?
No. As of October 3, 2026, retatrutide remains investigational. An online listing, trial result, or news report does not establish approval.
Does GLP-3 help with weight loss?
Retatrutide has produced substantial average weight loss in controlled research, but “GLP-3” is only an informal term. The findings do not guarantee an individual result or prove that an online vial contains retatrutide.
Is GLP-3 a pill or an injection?
Retatrutide has been studied as an injection. Products promoted as “oral GLP-3” should not be treated as approved oral retatrutide.
Can I buy a 20 mg retatrutide vial?
Websites may advertise vials under that name, but a label does not prove the contents, strength, sterility, or legal status. We do not recommend unapproved retatrutide products for self-treatment.
FAQ
Is GLP-3 a real hormone?
No. GLP-3 is not a recognized human hormone or FDA-approved drug class. It usually refers informally to retatrutide or triple receptor agonism.
What receptors does retatrutide target?
Retatrutide targets GLP-1, GIP, and glucagon receptors. That combination is why it is sometimes called a “triple G” medicine.
Is retatrutide available from pharmacies?
There is no FDA-approved retail retatrutide product as of the review date. Clinical-trial access is different from standard pharmacy access.
Are retatrutide and tirzepatide the same?
No. Retatrutide targets three receptor systems and remains investigational. Tirzepatide targets GIP and GLP-1 receptors, and approved tirzepatide products are available for labeled uses.
What can patients consider while retatrutide is investigational?
Eligible patients can discuss approved weight-management treatments with a licensed clinician. We recommend comparing medical suitability, side effects, product source, total cost, availability, and refill support.
Review an approved treatment instead
Use usetemi.com to review approved prescription and refill options with a licensed clinician, including the medication source, full cash price, shipping terms, and refill schedule.




